obsolete rare disease with dentinogenesis imperfecta
MONDO:0015669
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Dentinogenesis imperfecta
Dentinogenesis imperfecta (DI) is a genetic disorder of tooth development. It is inherited in an autosomal dominant pattern, as a result of mutations on chromosome 4q21, in the dentine sialophosphoprotein gene (DSPP). It is one of the most frequently occurring autosomal dominant features in humans. Dentinogenesis imperfecta affects an estimated 1 in 6,000-8,000 people. People with this condition have abnormal enamel, short and narrow roots to their teeth, and can have very small dental pulps (nerve). This condition can cause teeth to be discolored (most often a blue-gray or yellow-brown color) and translucent, giving teeth an opalescent sheen. Teeth are also less mineralized than normal, making them prone to rapid wear, breakage, and loss. These problems can affect primary (baby) teeth alone, or both baby teeth and permanent (adult) teeth, with the primary teeth usually more severely affected. Although genetic factors are the main contributor for the condition, any environmental or systemic changes that impede calcification or metabolization of calcium can also result in anomalous dentin.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.